Alsherbini K, Pandi A, Goyanes J, et al. - Since perampanel (PER) administration findings are β-amino-3-(5-methyl-3-oxo-1,2-oxazol-4-yl)propionic acid (AMPA) receptor antagonist for the treatment of refractory status epilepticus (RSE) and super-refractory (SRSE) have been reported previously in small cohort studies and case reports, researchers reported effectiveness and side effect results of an observational cohort of 75 patients treated with PER for RSE and SRSE. The sample consisted of patients with RSE admitted to the neurocritical care unit between April 2017 and September 2019 who received treatment with PER. In this retrospective cohort of RSE, the authors noted a definite response rate of 41.3% within 72 h of PER initiation. With few documented adverse effects, PER was well tolerated. To confirm the role of PER in treating patients with RSE, further prospective studies are required.